nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

13.10.2016

Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics

verfasst von: Chrisanna Dobrowolski, Edward G. Clark, Manish M. Sood

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The worldwide prevalence of chronic kidney disease is 10–15 % of the adult population, is rising and increases susceptibility to venous thromboembolism (VTE). In this narrative review we discuss the underlying evidence behind the association of VTE/CKD and examine the role of worsening CKD stage, proteinuria, and the risk of recurrent VTE. As CKD may alter therapeutic options we discuss the role of emerging therapies, the non-vitamin K oral anticoagulants (NOAC), in the treatment of VTE.

Arora P, Vasa P, Brenner D et al (2013) Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 185:E417–E423CrossRefPubMedPubMedCentral

Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J (2015) International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol 2015:184321CrossRefPubMedPubMedCentral

Wattanakit K, Cushman M (2009) Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med 15:408–412CrossRefPubMedPubMedCentral

Ng AC, Chung T, Yong AS et al (2011) Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 4:122–128CrossRefPubMed

Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41:3–14CrossRefPubMedPubMedCentral

Keller C, Katz R, Cushman M, Fried LF, Shlipak M (2008) Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 9:9CrossRefPubMedPubMedCentral

Shlipak MG, Fried LF, Crump C et al (2003) Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87–92CrossRefPubMed

Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K (2014) Haemostasis in chronic kidney disease. Nephrol Dial Transplant 29:29–40CrossRefPubMed

Al-Massarani G, Vacher-Coponat H, Paul P et al (2009) Kidney transplantation decreases the level and procoagulant activity of circulating microparticles. Am J Transplant 9:550–557CrossRefPubMed

10.

Camaioni C, Gustapane M, Cialdella P, Della Bona R, Biasucci LM (2013) Microparticles and microRNAs: new players in the complex field of coagulation. Intern Emerg Med 8:291–296CrossRefPubMed

11.

Statistics NCfH (2014) Survey results and products from the National Health and Nutrition Examination Survey. In: Centers for Disease Control and Prevention (ed) Hyattsville

12.

Centers for Disease Control and Prevention (2014) Chronic kidney disease surveillance system—United States

13.

Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol 12:464–474CrossRefPubMedPubMedCentral

14.

Christiansen CF, Schmidt M, Lamberg AL et al (2014) Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost 12:1449–1454CrossRefPubMed

15.

Kumar G, Sakhuja A, Taneja A et al (2012) Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol 7:1584–1590CrossRefPubMedPubMedCentral

16.

Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619CrossRefPubMed

17.

Kato S, Chernyavsky S, Tokita JE et al (2010) Relationship between proteinuria and venous thromboembolism. J Thromb Thrombolysis 30:281–285CrossRefPubMed

18.

Grams ME, Plantinga LC, Hedgeman E et al (2011) Validation of CKD and related conditions in existing data sets: a systematic review. Am J Kidney Dis 57:44–54CrossRefPubMed

19.

Vlasschaert ME, Bejaimal SA, Hackam DG et al (2011) Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis 57:29–43CrossRefPubMed

20.

Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR (2008) Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 19:135–140CrossRefPubMedPubMedCentral

21.

Folsom AR, Lutsey PL, Astor BC et al (2010) Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant 25:3296–3301CrossRefPubMedPubMedCentral

22.

Königsbrügge O, Lötsch F, Zielinski C, Pabinger I, Ay C (2014) Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res 134:44–49CrossRefPubMed

23.

Brodin EE, Brækkan SK, Vik A, Brox J, Hansen JB (2012) Cystatin C is associated with risk of venous thromboembolism in subjects with normal kidney function–the Tromsø study. Haematologica 97:1008–1013CrossRefPubMedPubMedCentral

24.

Shlipak MG, Matsushita K, Ärnlöv J et al (2013) Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 369:932–943CrossRefPubMedPubMedCentral

25.

Grubb A, Horio M, Hansson LO et al (2014) Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator. Clin Chem 60:974–986CrossRefPubMed

26.

Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP (2011) Endothelial dysfunction in diabetes. Diabetes Care 34:S285–S290CrossRefPubMedPubMedCentral

27.

Mahmoodi BK, Gansevoort RT, Veeger NJ et al (2009) Microalbuminuria and risk of venous thromboembolism. JAMA 301:1790–1797CrossRefPubMed

28.

van Schouwenburg IM, Mahmoodi BK, Veeger NJ, Kluin-Nelemans HC, Gansevoort RT, Meijer K (2012) Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. Br J Haematol 156:667–671CrossRefPubMed

29.

American College of Chest Physicians (2012) Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e691S–736SCrossRef

30.

Vílchez JA, Gallego P, Lip GY (2014) Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf 5:8–20CrossRefPubMedPubMedCentral

31.

Antithrombotic Therapy for VTE Disease: CHEST Guideline (2016) http://journal.publications.chestnet.org/article.aspx?preview=true&articleid=2479255, Accessed 21 Jan 2016

32.

Thrombosis Canada (2015) Clinical guides: venous thromboembolism

33.

Hughes S, Szeki I, Nash MJ, Thachil J (2014) Anticoagulation in chronic kidney disease patients-the practical aspects. Clin Kidney J 7:442–449CrossRefPubMedPubMedCentral

34.

Connolly SJ, Milling TJ, Eikelboom JW et al. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016

35.

Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352CrossRefPubMed

36.

Schulman S, Kearon C, Kakkar AK et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368:709–718CrossRefPubMed

37.

Bauersachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510CrossRefPubMed

38.

Büller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297CrossRefPubMed

39.

Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808CrossRefPubMed

40.

Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMed

41.

Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891CrossRefPubMed

42.

Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMed

Titel: Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics
verfasst von: Chrisanna Dobrowolski
Edward G. Clark
Manish M. Sood
Publikationsdatum: 13.10.2016
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 2/2017
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-016-1437-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia

Systemic thrombolysis in acute pulmonary embolism: also a matter of “time”

Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients

A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand

Novel sila-amide derivatives of N-acetylcysteine protects platelets from oxidative stress-induced apoptosis

Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin